BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 29712661)

  • 1. Incidence of Acute Kidney Injury among Patients Treated with Piperacillin-Tazobactam or Meropenem in Combination with Vancomycin.
    Rutter WC; Burgess DS
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712661
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect modification of dosing strategy (AUC or trough) on AKI associated with vancomycin in combination with piperacillin/tazobactam or cefepime and meropenem.
    Mefford B; Wallace KL; Donaldson JC; Bissell Turpin BD; Sen P; Schadler AD; Liu LJ; Thompson Bastin ML
    Antimicrob Agents Chemother; 2024 May; 68(5):e0108523. PubMed ID: 38606975
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of combining vancomycin with piperacillin/tazobactam or with meropenem on vancomycin-induced nephrotoxicity.
    Tookhi RF; Kabli NA; Huntul MA; Thabit AK
    Intern Emerg Med; 2021 Jun; 16(4):975-979. PubMed ID: 33439417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nephrotoxicity during Vancomycin Therapy in Combination with Piperacillin-Tazobactam or Cefepime.
    Rutter WC; Cox JN; Martin CA; Burgess DR; Burgess DS
    Antimicrob Agents Chemother; 2017 Feb; 61(2):. PubMed ID: 27895019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute kidney injury with combination vancomycin and piperacillin-tazobactam therapy in the ICU: A retrospective cohort study.
    O'Callaghan K; Hay K; Lavana J; McNamara JF
    Int J Antimicrob Agents; 2020 Jul; 56(1):106010. PubMed ID: 32413387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Acute Kidney Injury Among Patients Receiving the Combination of Vancomycin with Piperacillin-Tazobactam or Meropenem.
    Robertson AD; Li C; Hammond DA; Dickey TA
    Pharmacotherapy; 2018 Dec; 38(12):1184-1193. PubMed ID: 30175410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of teicoplanin versus vancomycin in combination with piperacillin-tazobactam or meropenem for the risk of acute kidney injury.
    Aslan AT; Pashayev T; Dağ O; Akova M
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1953-1961. PubMed ID: 33884515
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the Nephrotoxicity of Vancomycin in Combination With Cefepime, Meropenem, or Piperacillin/Tazobactam: A Prospective, Multicenter Study.
    Mullins BP; Kramer CJ; Bartel BJ; Catlin JS; Gilder RE
    Ann Pharmacother; 2018 Jul; 52(7):639-644. PubMed ID: 29442542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of Acute Kidney Injury Among Critically Ill Patients With Brief Empiric Use of Antipseudomonal β-Lactams With Vancomycin.
    Schreier DJ; Kashani KB; Sakhuja A; Mara KC; Tootooni MS; Personett HA; Nelson S; Rule AD; Steckelberg JM; Tande AJ; Barreto EF
    Clin Infect Dis; 2019 Apr; 68(9):1456-1462. PubMed ID: 30165426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern?
    Balcı C; Uzun Ö; Arıcı M; Hayran SA; Yüce D; Ünal S
    Int J Antimicrob Agents; 2018 Aug; 52(2):180-184. PubMed ID: 29649586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective Cohort Study of the Incidence of Acute Kidney Injury with Vancomycin Area under the Curve-Based Dosing with Concomitant Piperacillin-Tazobactam Compared to Meropenem or Cefepime.
    Kiley PS; Pearston AP; Hodge LA; Kaplan MC; Baczek SM; Stanley JS; Wilson TJ; Soriano KM; Yao A; Shaeffer ZA; Talt IE; Cohen JA; Ingemi AI
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0004022. PubMed ID: 35867523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative incidence and excess risk of acute kidney injury in hospitalised patients receiving vancomycin and piperacillin/tazobactam in combination or as monotherapy.
    Carreno J; Smiraglia T; Hunter C; Tobin E; Lomaestro B
    Int J Antimicrob Agents; 2018 Nov; 52(5):643-650. PubMed ID: 30103003
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam.
    Alosaimy S; Lagnf AM; Hobbs ALV; Mubarez M; Kufel WD; Morrisette T; Polisetty RS; Li D; Veve MP; Simon SP; Truong J; Finch N; Venugopalan V; Rico M; Amaya L; Yost C; Cubillos A; Chandler E; Patch M; Smith IMK; Biagi M; Wrin J; Moore WJ; Molina KC; Rebold N; Holger D; Kunz Coyne AJ; Jorgensen SCJ; Witucki P; Tran NN; Davis SL; Sakoulas G; Rybak MJ
    Clin Infect Dis; 2023 Feb; 76(3):e1444-e1455. PubMed ID: 35982631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Risk of Acute Kidney Injury in Patients Treated with Vancomycin and Piperacillin/Tazobactam Compared to Vancomycin and Meropenem or Doripenem: A Retrospective Cohort Study].
    Ide N; Sato S; Sawaguchi K
    Yakugaku Zasshi; 2019; 139(12):1609-1614. PubMed ID: 31787651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vancomycin With Concomitant Piperacillin/Tazobactam vs. Cefepime or Meropenem Associated Acute Kidney Injury in General Ward Patients: A Multicenter Propensity Score-Matched Study.
    Komerdelj IA; Buckley MS; D'Alessio PA; Ziadat DS; Kobic E; Rangan P; Agarwal SK; Tinta NC; Yerondopoulos MJ; Kane-Gill SL
    J Pharm Pract; 2024 Feb; 37(1):80-87. PubMed ID: 36075000
    [No Abstract]   [Full Text] [Related]  

  • 16. Piperacillin/Tazobactam and Antibiotic-Associated Acute Kidney Injury in Critically Ill Children.
    Joyce EL; Kane-Gill SL; Priyanka P; Fuhrman DY; Kellum JA
    J Am Soc Nephrol; 2019 Nov; 30(11):2243-2251. PubMed ID: 31501354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of β-Lactam Infusion Strategy on Acute Kidney Injury.
    Cotner SE; Rutter WC; Burgess DR; Wallace KL; Martin CA; Burgess DS
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Large-Scale Multicenter Retrospective Study on Nephrotoxicity Associated With Empiric Broad-Spectrum Antibiotics in Critically Ill Patients.
    Chen AY; Deng CY; Calvachi-Prieto P; Armengol de la Hoz MÁ; Khazi-Syed A; Chen C; Scurlock C; Becker CD; Johnson AEW; Celi LA; Dagan A
    Chest; 2023 Aug; 164(2):355-368. PubMed ID: 37040818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vancomycin with concomitant piperacillin/tazobactam vs. cefepime or meropenem associated acute kidney injury in the critically ill: A multicenter propensity score-matched study.
    Buckley MS; Komerdelj IA; D'Alessio PA; Rangan P; Agarwal SK; Tinta NC; Martinez BK; Ziadat DS; Yerondopoulos MJ; Kobic E; Kane-Gill SL
    J Crit Care; 2022 Feb; 67():134-140. PubMed ID: 34768175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative incidence of acute kidney injury in patients on vancomycin therapy in combination with cefepime, piperacillin-tazobactam or meropenem.
    Rungkitwattanakul D; Ives AL; Harriott NG; Pan-Chen S; Duong L
    J Chemother; 2022 Apr; 34(2):103-109. PubMed ID: 34424136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.